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Summary Antibodies directed against tumour associated antigens provide a means for delivering
preferentially cytotoxic radionuclides to the cells of primary and secondary tumours. The factors that
influence the effectiveness of the radiation in the tumour compared with its effect on the radiosensitive
normal tissues include the specificity of the antibody, the distribution of targeted energy within the tumour
and the host's response to the injected foreign antibody. Recently some encouraging results from clinical trials
of radioimmunotherapy have been reported in the literature. There is a continual search for more avid and
specific antibodies, and the techniques of genetic engineering are being applied to the problem of reducing the
antigenicity and mass of the carrier antibody. The improved efficiency of the labelled antibody needs to be
supplemented by an identification of those tumours most likely to respond to this form of therapy.
There is growing interest in the possibility of
treating disseminated malignant disease by
antibody-targeted cytotoxic radionuclides. The
impetus for this comes from three sources. First,
the introduction of monoclonal antibodies
(McAbs), which allows more precise targeting than
has been possible with polyclonal antibodies.
Second, the improved gamma and positron tumour
immunoimaging that can be obtained with McAbs
has illustrated clearly that radionuclides can be
concentrated in tumours. Third, there have been a
number of reports indicating clinical response to
antibody-targeted radionuclides (Order et al., 1980a
1985; Carrasquillo et al., 1984). Order and his
colleagues at the Johns Hopkins Hospital,
Baltimore, have been using radiolabelled polyclonal
antibodies as a part of their treatment of carcinoma
of the liver (hepatocellular and cholangio-
carcinoma) for some years, and have reported
clinical responses with radiation/drug regimens
which include 131I-labelled anti-ferritin and anti-
carcinoembryonic antigen (CEA). Using the same
isotope of iodine, attached to a murine McAb
against p97, an oncofoetal glycoprotein of human
melanoma, Carrasquillo and his colleagues (1984)
have reported clinical regression in malignant
melanoma.
The stage would now seem to be set for
significant advances in this field. It is a technically
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complex form of therapy requiring a multi-
disciplinary approach, calling upon immunologist,
clinician, radiochemist, radiobiologist and physicist
alike. In this review we shall examine in turn the
target, the carrier and the radionuclide 'warhead'
and finally comment upon the problems and
possibilities of this form of treatment.
Target
The target for the administered ionizing radiation is
the DNA of the malignant cells - or more
particularly the DNA of the malignant 'stem' cells.
The sterilizing effect of radiation is thought to be
due predominantly to the induction of double
strand breaks (DSB). From in vitro studies with
Ehrlich ascites tumour cells Blocher (1981, 1982)
found that for low Linear Energy Transfer (LET)
radiation (photons, electrons) an average of -200
DSB is required per cell to sterilize -99% of a
tumour cell population. For high LET radiation (a
particles) it is likely that somewhat fewer DSB are
required.
One advantage that targeted radiation has over
antibody targeted toxins is that a tumour cell
without the appropriate antigenic determinant can
yet be sterilized by the radiation cross-fire from
adjacent cells having the determinant and binding
the labelled antibody. The sterilizing efficiency of
the cross-fire effect will depend to a large degree
upon the spatial arrangement of the malignant
'stem' cells with respect to the labelled carrier
antibody. We know from immunohistochemical
©) The Macmillan Press Ltd., 1986864 L.M. COBB & J.L. HUMM
studies of human tumour biopses that many of the
McAbs directed against tumour-associated
membrane antigens will attach to the surface of
only a proportion of the malignant cells (antigenic
heterogeneity) (Burchiel et al., 1982; Wright et al.,
1983; Edwards et al., 1985; Fargion et al., 1986).
Foster et al. (1982a, b) have observed such
heterogeneity of antigenic expression in primary
breast cancer and the associated lymph node metas-
tases using a McAb to human milk fat globule
membrane (HMFG). They also observed antigenic
heterogeneity within the different cell types of
normal breast tissue. Wright et al. (1983) examined
human prostatic carcinomas, both primary and
secondary tumours, using a specific anti-prostatic
carcinoma McAb and recorded the distribution of
antigen as being either in a patchwork in which the
binding and non-binding cells seemed to alternate,
or one in which large areas of tumour devoid of
binding sites alternated with high binding areas.
Antigenic heterogeneity has been observed in a
number of other human tumours (Hand et al.,
1983; Natali et al., 1983), and on cultured human
cells (Albino et al., 1981; Burchiel et al., 1982) and
has variously been associated with heterogeneity of
cell size (Burchiel et al., 1982) cell function (Foster
et al., 1982a), stage of cell cycle (Burchiel et al.,
1982; Kufe et al., 1983) and invasiveness (Suter et
al., 1985).
Whatever the explanation(s) of antigenic hetero-
geneity there seems to be little doubt that in many
tumours it will result in a very uneven distribution
of targeting antibody. The cross fire effect will in
part compensate for this. It is also possible that
polyclonal antibody can reduce the unevenness.
Otherwise the solution may be in the use of McAb
'cocktails' (Natali et al., 1983; Carrasquillo et al.,
1984). Another possibility is the use of biological
response modifiers (BRM) to increase antigen
expression. Recently, Greiner and his colleagues
(1984) illustrated an increase in the expression of
tumour associated antigenic determinants, both cell
membrane density and the number of cells
expressing the antigen, when human breast or colon
carcinoma cells were cultured in the presence of the
BRM recombinant human leukocyte a-interferon.
Edwards (1985), in his excellent review of
antigenic heterogeneity in tumours, suggested that
there may be less heterogeneity associated with
protein rather than carbohydrate determinants and
that we should be examining more carefully McAbs
to the protein portion of cell membrane glyco-
proteins. In their work with human melanoma cell
lines Burchiel et al. (1982) observed that antigenic
heterogeneity appeared as a range of concentration
of antigen, rather than an 'all or none' situation. If
this reflects the in vivo position it would indicate
that many of the cells in a tumour may still bear
tumour-associated antigen, but in low concen-
trations. Under such circumstances a high degree of
cell sterilization could still be achieved, and cells
with few binding sites killed, if the radioactivity
were to be delivered by small numbers of antibody
molecules heavily laden with a ,B emitter. The
alternative is to use an cx emitter (not more than
one atom per molecule), or a radionuclide that
decays by electron capture and/or internal
conversion in which prolific emission of low energy
(Auger) electrons occurs. In the latter case, as
Auger electrons have ranges predominantly of
<1tIm, a mechanism would have to be found for
positioning the radionuclide in close proximity to
the DNA of the target cell (Hofer, 1980), vide infra.
Carrier
The purpose of the carrier antibody is to deliver to
the disseminated tumour cells sufficient radio-
activity to sterilize them. Although attention is
naturally focussed on delivering high levels of
activity as quickly as possible to the tumour it is
equally important that the retention time of the
radionuclide in the tumour relative to that in the
dose-limiting normal tissue should be for as long as
possible (DeNardo et al., 1982). To maximise the
ratio of tumour to non-tumour dose we support the
view of DeNardo et al. (1983) that the physical
half-life of the radionuclide should be similar to the
biological half-life of the carrier antibody in the
tumour. Unfortunately, the latter half-life is not
easily measured, but can be expected to vary
greatly from one tumour to the next (Leichner et
al., 1983; Rostock et al., 1984; Klein et al., 1985).
Larson et al. (1983) have reported an effective half-
life (composite of biological and physical half-lives)
of 46h in melanoma following injection of a patient
with 1311-labelled Fab fragments of an anti-
melanoma McAb. Using 131I-labelled antiferritin
polyclonal antibody, Leichner and his colleagues
(1983) reported effective half-lives within the
patient's primary hepatoma of between 0.25 and 7.8
days - depending upon the method of purification
and the subsequent diluent of the administered
antibody.
The documented positive clinical response to
targeted radiation has been almost entirely with
polyclonal antibody as carrier (Order et al., 1980a;
1981). In order to give repeated injections of
labelled targeting antibody and avoid patient
sensitization to foreign antibody these authors used
polyclonal antibody from a different species for
each injection (Order et al., 1985). There has not
been sufficient time for a realistic clinical
assessment of the value of McAbs in radioimmuno-
therapy (RIT); however, it would seem that the
more specific targeting potentially obtainable withRADIOIMMUNOTHERAPY 865
McAbs should offer an improvement over
polyclonal antibodies.
There is as yet no clinical evidence for the
increased value as carrier of enzyme-digested frag-
ments of Ig above the parent molecule. However,
the experimental evidence so far points to a distinct
advantage in the use of such fragments (DeNardo
et al., 1983; Buraggi et al., 1985). The preparation
of F(ab')2 fragments removes the problem of Ig
binding to Fc receptors in the liver which otherwise
produces a rapid and wasteful accumulation of
radionuclide in that organ (Buraggi et al., 1985).
The use of Fab and similar univalent fragments
should prevent antigenic modulation and the
associated fall-off in retention by the tumour cells
of injected antibody (Glennie & Stevenson, 1982;
Cobbold & Waldmann, 1984). On the other hand
antibody fragments may be less well retained by the
tumour and therefore the radiation dose to the
tumour cells reduced.
The factors controlling the loss of antibody or
antibody fragment from the tumour and its intra-
and extra-tumour catabolism are ill understood.
There is however clear evidence from both human
and animal systems that antibody fragments are
more rapidly cleared from the body than is the
parent immunoglobulin (Ig) (Buraggi et al., 1985).
No one has been surprised to find that the
administration of xenogeneic antibody produces on
the first or subsequent injection an immune
response by the patient to the foreign protein
(Primus et al., 1980; Carrasquillo et al., 1984).
What has perhaps been surprising is the amount of
foreign antibody that can be injected. Meeker and
his colleagues (1985) were able to inject into
patients with a minimum of side effects 40-400mg
of mouse McAb on 6-9 occasions over 3 weeks to
totals in excess of 3000mg. The response by
patients to foreign antibody may in time be
circumvented, or at least greatly reduced, by the use
of human monoclonal antibody (Sikora et al.,
1985). Additionally, recent advances in genetic
engineering now make it possible to prepare human
Ig with high avidity rodent variable regions.
Sahagan et al. (1986) have shown that murine
variable and human constant region exons can be
fused to produce 'chimaeric' immunoglobulin y and
K genes and that these constructs when co-
transfected into murine myeloma cells can secrete
intact, functional, antibody. These cells when grown
as an ascites in mice produce antibody with similar
specificity for epitopes on human tumour cells as
the parent murine McAb.
Complexes formed from the injected, labelled,
foreign (antigenic) antibody and the host (reactive)
antibody can accumulate in the reticuloendothelial
system (RES) and kidneys producing a harmful
radiation dose. In a similar way immune complexes
formed from circulating tumour antigen and
injected (labelled) specific antibody will increase the
radiation dose to the RES and kidneys at the
expense of the tumour dose (Dillman et al., 1984).
The problem of circulating tumour antigen is well
recognised (Nadler et al., 1980; Warenius et al.,
1981; Hagan et al., 1983). Unfortunately it remains
a significant stumbling block in RIT. In B cell
tumours, where the labelled antibody is commonly
directed against the idiotype of the antibody
secreted by the tumour cell, some reduction in
circulating antigen (lymphoma-secreted antibody)
can be obtained by plasmaphoresis, but the
reduction is short-lived (Hamblin et al., 1980;
Meeker et al., 1985).
It can be argued that once a tumour has taken
up a significant amount of labelled antibody there
is an advantage in then clearing the blood of
residual circulating antibody in order to reduce the
irradiation of the sensitive normal tissues, e.g., bone
marrow. Begent and his colleagues (1982, 1984)
have shown that significant clearance can be
achieved by using a second antibody directed
against the first (labelled) antibody which leads to
the sequestration of the labelled antibody in the
spleen and liver. The advantage thus gained from
protection of the particularly radiosensitive tissues
needs to outweigh the disadvantage from the
accelerated clearance of antibody from the tumour
that results from a lowered level of circulating
antibody. It is also important that the RES itself is
not seriously damaged by the sequestrated labelled
antibody.
One of the factors that will control the speed of
uptake of antibody by the tumour is the ease with
which the antibody can cross the capillary wall. We
know that in normal tissues the permeability of
capillaries varies between organs and in those
organs with fenestrated capillaries (e.g. thyroid,
bone marrow, renal glomerulus, liver, spleen,
choroid plexus) there is a very rapid passage of
macromolecules. If malignant cells originating from
these tissues should stimulate the host organ to
produce similarly fenestrated capillaries for their
support these tumours might be good candidates
for RIT. Ludatscher et al., (1979) in an ultra-
structural study of follicular carcinoma of the
thyroid have indeed shown fenestration of the
tumour capillary bed. In a similar examination of
brain metastases from carcinoma of the kidney,
Hirano and Zimmerman (1972) have reported the
formation of fenestrated capillaries to support the
infiltrating cell population.
Radionuclides
Satisfactory tumour localization can be obtained in
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variously labelled with 109Pd (Fawwaz et al., 1984),
1311 (Goldenberg et al., 1981; Zalcberg et al., 1984;
Badger et al., 1985), 90Y (Hnatowich et al., 1985)
and 21'At (Vaughan et al., 1982; Bateman et al.,
1983); but only 1311 has so far been used clinically.
Much of the clinical work in this area has been
carried out by Order and his colleagues (Ettinger et
al., 1979; Order et al., 1980a,b; Order et al., 1981;
Leichner et al., 1984). They have reported a
significant response in hepatocellular carcinoma to
131I-anti-ferritin, and by biliary tract carcinoma to
131I-anti-CEA, when used as part of a complex
drug/radiation regimen. They believe that the
radiation plays a significant role in the regimen.
Carrasquillo and his. colleagues (1984) have used
131I-labelled McAb directed against the p97 antigen
in melanoma patients and record some beneficial
response. Courtenay-Luck et al. (1984), Epenetos et
al. (1985) and Pectasides et al. (1986) have reported
a degree of success with locally injected 1311-
labelled anti-HMFG and anti-epidermal growth
factor receptor. These workers injected the labelled
McAb either directly into the tumour infiltrated
body cavity or into the artery supplying the
tumour.
Iodine-131 has, over many years, proved its
tumourdestructive capacity in thyroid carcinoma and
it was therefore natural to use this radionuclide for
antibody-targeted therapy. It has the additional
advantages that the chemistry of antibody labelling
is well researched and the radionuclide is relatively
cheap. However, the variation in the pattern of
distribution of malignant stem cells within the
tumour mass, the variation in diameter of primary
tumours and their metastases and the different
retention time of different antibodies makes it
unlikely that any one radionuclide will be suitable
on all occasions.
As we have observed above, one therapeutic
approach to the problem of a low number of
binding sites per tumour cell is to use a radio-label
with high cytotoxic efficacy. The x-particle emitting
radionuclides fall into this class and a number of
research groups are pressing the case for the use of
a emitters in RIT (Vaughan et al., 1982; Harrison
& Royle, 1984; Kozak et al., 1986). Harrison and
Royle (1986) have shown that astatine-211 labelled
McAb can cure early T cell lymphoma in mice, and
Kozak and his co-workers (1986) have reported
that in vitro bismuth-212 labelled anti-Tac greatly
reduces the proliferative capacity of a human T cell
lymphoma line. The number of suitable a emitters
is small but bismuth-212 (T (half-life)=1 h] may be
induced in situ by administering the parent lead-212
(T=10-6h] which decays by fl-emission to the cx
emitting daughter bismuth-212 and its daughter
polonium-212 (T=304 ns). Although a particles are
very efficient in sterilizing tumour cells it should be
remembered that they will be equally efficient in
sterilizing many normal cells - and that while with
f emission fractionation of treatment allows time
for normal tissues to repair, such repair does not
follow a particles irradiation. An advantage of a
particles which may be important with some
tumours is that the protective effect of hypoxia seen
with f radiation does not occur.
There are other decay processes, namely electron
capture and internal conversion, that can result in
even more local energy deposition effects than a
emission. Both electron capture and internal
conversion result in the removal of an inner shell
orbital electron from the atom, usually in the
K-shell. This introduction of an inner shell
vacancy into the atom initiates a cascade of electron
transitions which can result in the emission of a
number of very low energy Auger electrons of the
order of a few keV or fraction thereof whose ranges
can span from a few nanometres to a few micro-
metres. The prolific emission of Auger electrons
from 125I has been shown to be extremely effective
when it is incorporated directly into the DNA
using the thymidine precursor iododeoxyuridine
(Burki et al., 1973; Feinendegen, 1975; Liber et al.,
1983). Because of the short range of most Auger
electrons the effectiveness in cell inactivation of
sources like 1251 or 119Sb is mostly lost when they
are not bound to, or sited within, a few atomic
spaces of the DNA (Hofer, 1980).
The problem is to introduce these Auger emitters
preferentially into the DNA helix of the tumour
cells. In their study of 125I-labelled DNA inter-
calating substances Martin and his co-workers
(Martin, 1977; Martin et al., 1979) have shown how
effective these labelled compounds are at producing
DSB. Working in a different but related area
Diener et al. (1986) have shown specific sterilization
of T lymphocytes in vitro using a cytotoxic DNA
intercalating drug (daunomycin) linked to a T cell
specific McAb. After internalization of the
antibody-daunorubicin conjugate the drug was
uncoupled in the lysosomes by the dissociation of
an acid sensitive aconityl linkage. There would
seem to be a future for labelling such DNA inter-
calating agents with Auger emitters and linking
them to specific McAbs so that they would be
preferentially introduced into tumour cells, and not
bone marrow and other sensitive tissues - and the
intercalating agent would subsequently introduce
the Auger emitter into the tumour cell DNA helix.
Normal tissues
In focussing attention on methods for increasing
the deposition of energy in the tumour it is essential
that a similar increase does not occur in the energyRADIOIMMUNOTHERAPY 867
deposited in the bone marrow or other critical
tissue. In clinical practice this problem is tackled by
experience gained from monitoring of haemato-
logical and blood biochemical parameters during
and after therapy.
The most informative clinical toxicology yet
available comes from the clinic and laboratories of
Dr S.E. Order. For example, 14 patients were
evaluated during the treatment of primary liver
cancer with 131I-labelled polyclonal antibody
(Ettinger et al., 1982). The 14 patients received
activities between 1.4 xl09Bq and 5.8 xl09Bq of
1311 and the main toxicity was to bone marrow.
Seven of the 14 patients had severe life-threatening
leukopenia and thrombocytopenia. The lowest
activity of 1311 to produce severe haematoxicity was
3.4 x 109 Bq which gave absorbed doses to the total
body, liver and tumour of 1.4, 6 and 19Gy
respectively. This patient had a partial tumour
response. The next highest injected activity
(3.7 x 109 Bq 1311), which was without effect on the
tumour, gave total body, liver and tumour
absorbed doses of 1.1, 4 and 15Gy. In this case
there was no bone marrow toxicity but there was a
transient rise in certain circulating hepatic enzymes.
These results with polyclonal antibody can be
compared with those of Larson et al. (1983) where
they treated malignant melanoma with 131I-labelled
Fab fragments of McAb IgG seeing p97, an
oncofoetal glycoprotein of human malignant
melanoma. The administration of 3.7 x 109 Bq 1311
resulted in an absorbed dose to bone marrow, liver
and tumour was 0.3, 3 and 1OGy respectively. They
considered the bone marrow to be the critical organ
and reported leukopenia and thrombocytopenia
at a cumulative activity of 2 x 1010 Bq 131I.
These authors stressed that a large variation
between patients in tissue absorbed dose can be
expected, due in part to differences between
preparations of 131I-labelled antibody and in part
to the interaction of the antibody and the patient.
It should be remembered that when comparisons of
dose-effects are being made the period of time over
which a dose is absorbed has to be taken into
consideration as does the fractionation regimen - as
they both have a bearing on tissue repair.
It is a common finding in gamma scintigraphy
that the radionuclide accumulates extensively in the
liver and spleen. Not only can this interfere with
the interpretation of the scan but also it indicates
that with the higher activities used in therapy the
dose-limiting radiotoxic effect may be to these
organs rather than to the bone marrow (Ettinger et
al., 1982; Frank et al., 1983). In other circumstances
the kidney could be the normal tissue most affected.
This may arise from localization of radiolabelled
immune complexes or Ig fragments, or because use
is being made of a radioisotope of an element that
concentrates in the kidney. For example, 109Pd-
labelled anti-melanoma McAb is seen to give rise to
the accumulation of 109Pd in the kidney of
experimental animals (Fawwaz et al., 1984). There is
an isotope of mercury with potential therapeutic
value ('97Hg) but this element can be retained by
the proximal convoluted tubules of the kidney.
Where this is any suspicion of the accumulation of
a radionuclide in a confined area within an organ,
e.g., a particular cell type, estimations of the local
absorbed dose and not simply the absorbed dose to
the whole organ should be made.
Prospectsfor radioimmunotherapy
The treatment of cancer with targeted radionuclides
(zetotherapy=to treat by seeking out; (4t£o=to
seek out) is an area of radiotherapy that with our
present state of knowledge appears to have
considerable potential. For this potential to be
realised there are problems that need to be
addressed and resolved.
(i) Antigenic heterogeneity The erratic distribution
of binding sites throughout a tumour is likely to
produce a similarly erratic deposition of energy in
the tumour cell population. There are a number of
approaches being adopted to try to achieve a more
uniform radiation dose. In the forseeable future it
would appear that success is most likely to come
from the use of a combination of McAbs directed
against different epitopes or from the production of
new McAbs to less heterogeneously distributed
tumour-associated antigens.
(ii) Specificity of antibody Many of the presently
available antibodies localize in areas other than the
tumour. It is important that the search continues
for carriers that will preferentially localize in
tumours.
(iii) Fractionation ofradiation With external irradia-
tion fractionation of the dose is used to give the
normal tissues time to repair. The same principle
will apply with # emitters - but not with a emitters,
and probably not with Auger cascades. The
difficulty with fractionation of the dose with RIT
is that at present we have the major problem of
the antigenicity of the carrier. The pragmatic and
seemingly successful approach to this problem
made by Order and his colleagues (1985) has been
to use a succession of polyclonal antibodies raised
in different species of animal. An obvious alterna-
tive is to employ genetic engineering to build carrier
molecules with a minimum of antigenicity -
although we are still left with the antigenicity of the
idiotype. In the more distant future we may be able868 L.M. COBB & J.L. HUMM
to approach the problem by blocking either the
patients' recognition of the foreign antibody or the
ability to respond to it.
(iv) Access ofantibody to target antigen An estimate
can be made of the radioactivity in a tumour mass
usingyscintigraphyorpositron-emissiontomography.
This does not however provide information
on the microscope distribution of activity, which
is essential before any estimate can be made of the
proportion of tumour cells likely to be sterilized or
give advice on the most appropriate radionuclide.
This information can only be obtained from
biopsies of the tumour in the days following the
injection of labelled antibody - and such material is
rarely available. This represents a major gap in our
knowledge. We can make the assumption that the
capillaries in a rapidly growing tumour will be
relatively permeable to antibody - but such may
not be the case in the common slow growing
tumours, and we may need to seek ways for
improving tumour capillary permeability. Efforts
are continually being made to reduce the size of the
carrier molecule in an attempt to improve access to
extravascular sites. The molecule shape and charge
need also to be considered.
As with all new forms of tumour therapy the
initial optimism will become tempered with
experience. Our aim must therefore be to try to
identify as quickly as possible those categories of
patients who will benefit by the inclusion of RIT in
their treatment regimen.
We particularly wish to acknowledge the valuable
assistance provided by numerous discussions with Mrs A.
Harrison of this Unit. Dr J. Savage suggested the term
zetotherapy.
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